fulltext- http://www.mediafire.com/?ynu86rd2380pb9y
The tale of xenotropic murine leukemia virus-related virus
Harriet C.T. Groom and Kate N. Bishop1
Abstract
In 2006, a new retrovirus was isolated from prostate cancer patient
tissue. Named xenotropic murine leukemia virus-related virus (XMRV),
this was potentially the third class of retrovirus to be pathogenic in
humans. XMRV made a more dramatic impact on the wider scientific
community, and indeed the media, in 2009 when it was reported to be
present in a remarkably high proportion of patients with chronic
fatigue syndrome as well as a significant, albeit smaller, proportion
of healthy controls. The apparent strong link to disease and the fear
of a previously unknown retrovirus circulating in the general
population lead to a surge in XMRV research. Subsequent studies failed
to find an association of XMRV with disease and, in most cases, failed
to find the virus in human samples. In 2011, the case against XMRV and
human disease strengthened, ending with several decisive publications
revealing the origin of the virus and demonstrating contamination of
samples. In this review, we outline the passage of research on XMRV
and its potential association with disease from its isolation to the
present day, where we find ourselves at the end of a turbulent story.
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
